Psychedelic Pharmaceutical Startup Ninnion Announces Patent Filings and Development of NIN-S119 for Ischemic Stroke Novel therapy set to be administered in low doses with no psychedelic effects
AUSTIN, Texas
|
April 07, 2022 11:33 AM Eastern Daylight Time
Ninnion, a clinical-stage pharmaceutical company focused on developing next-generation psychedelic therapeutics, today announced the commencement of a first-of-its-kind pre-clinical development of NIN-S119. NIN-S119 is a proprietary, short-acting substituted tryptamine to treat patients recovering from ischemic stroke. It would be the first drug of its kind in the treatment of stroke, potentially making it eligible for Breakthrough Therapy designation by the FDA, a designation that can accelerate the development timeline.
“Ninnion saw a big opportunity to develop NIN-S119, as there are no approved drug therapies for patients recovering from a stroke. It will be used in conjunction with physical/occupational therapy to enhance stroke recovery by inducing neuroplasticity – meaning it induces the formation of new connections between nerve cells in the brain. This sort of brain ‘rewiring’ could prove beneficial for stroke recovery by creating new brain circuitry that could restore function to brain areas damaged by stroke,” said Bill W Massey, Chief Development Officer of Ninnion.
While drugs of this class that produce neuroplastic effects can induce psychedelic experiences (e.g. LSD, mescaline, DMT, etc.), one major benefit of NIN-S119 is that even though it's in this class of drugs, it could potentially be administered in low doses that do not produce these experiences. This would make NIN-S119 much easier to use clinically, reducing the time and effort of clinical staff and opening the potential for administration by the patient at home.
“After experiencing multiple health issues, including three strokes in one year, I began researching and reading all about how to repair the brain through the neuroplasticity and neurogenesis effects of psychedelics. We created Ninnion to not only develop a new way to treat strokes but more importantly, to bring these drugs to market in a responsible way.
The way psychedelic therapies are set up now is not helpful for the payer-reimbursed market. We want to create therapies that are accessible and affordable; patients should not have to pay thousands of dollars for therapies out of pocket. We’re encouraged by recent patent approvals for the development and delivery of new psychedelic therapies and we’re looking forward to advancing our clinical trials and continuing to develop other molecules in our pipeline,” said Jeremy M Caudill, Founder, and CEO of Ninnion.
Ninnion’s research and development efforts currently focus on advancing next-generation psychedelic therapies, which will ultimately empower patients with more accessible and affordable treatment opportunities.
To find out more about the study and Ninnion’s NIN-S119 molecule, visit www.ninnion.com/.
About Ninnion
Headquartered in Austin, Texas, Ninnion is a pharmaceutical company on a mission to build a fully integrated pharmaceutical psychedelics eco-system leveraging the latest AI drug discovery, development, cGMP manufacturing, commercialization, patient clinics and specialty pharmacy distribution network designed for the next frontier of psychedelic medicine. Focused on the payer-reimbursed market, Ninnion has begun developing a pipeline of next generation psychedelic therapies with a clinical focus on brain injury, chronic pain, inflammation, and addiction disorders. To learn more, visit www.ninnion.com.
Contact Details
Jive PR + Digital
Ashley Areeda
+1 734-891-4013
